SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-018536
Filing Date
2023-03-08
Accepted
2023-03-08 16:05:58
Documents
12
Period of Report
2023-03-02
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea174799-8k_tffpharma.htm   iXBRL 8-K 26220
  Complete submission text file 0001213900-23-018536.txt   201291

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE tffp-20230302.xsd EX-101.SCH 3230
3 XBRL LABEL FILE tffp-20230302_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE tffp-20230302_pre.xml EX-101.PRE 22361
6 EXTRACTED XBRL INSTANCE DOCUMENT ea174799-8k_tffpharma_htm.xml XML 3702
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

IRS No.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39102 | Film No.: 23716159
SIC: 2834 Pharmaceutical Preparations